Øystein S. Sandanger
- Researcher; MD, PhD
Research topics: Immunology, psoriasis
Publications 2024
Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials
Lancet Rheumatol, 6 (4), e226-e236
DOI 10.1016/S2665-9913(23)00341-7, PubMed 38402891
Chronic HIV Infection Increases Monocyte NLRP3 Inflammasome-Dependent IL-1α and IL-1β Release
Int J Mol Sci, 25 (13)
DOI 10.3390/ijms25137141, PubMed 39000248
CD38 deficient mice are not protected from atherosclerosis
Biochem Biophys Res Commun, 705, 149734
DOI 10.1016/j.bbrc.2024.149734, PubMed 38430607
Publications 2023
HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases
J Intern Med, 293 (5), 648-655
DOI 10.1111/joim.13616, PubMed 36843323
Publications 2022
Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial
J Intern Med, 292 (3), 477-491
DOI 10.1111/joim.13495, PubMed 35411981
Publications 2021
Targeting the Inflammasome in Cardiovascular Disease
JACC Basic Transl Sci, 7 (1), 84-98
DOI 10.1016/j.jacbts.2021.08.006, PubMed 35128212
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial
JAMA, 325 (17), 1744-1754
DOI 10.1001/jama.2021.4172, PubMed 33944876
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial
JAMA, 326 (23), 2375-2384
DOI 10.1001/jama.2021.21316, PubMed 34932077
Publications 2020
Cholesterol crystals use complement to increase NLRP3 signaling pathways in coronary and carotid atherosclerosis
EBioMedicine, 60, 102985
DOI 10.1016/j.ebiom.2020.102985, PubMed 32927275
Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study)
Trials, 21 (1), 13
DOI 10.1186/s13063-019-3734-4, PubMed 31907007
Publications 2019
Mammalian Target of Rapamycin (mTOR) and the Proteasome Attenuates IL-1β Expression in Primary Mouse Cardiac Fibroblasts
Front Immunol, 10, 1285
DOI 10.3389/fimmu.2019.01285, PubMed 31244838
Low Cellular NAD+ Compromises Lipopolysaccharide-Induced Inflammatory Responses via Inhibiting TLR4 Signal Transduction in Human Monocytes
J Immunol, 203 (6), 1598-1608
DOI 10.4049/jimmunol.1801382, PubMed 31427442
Publications 2017
Toll-Like Receptor 9 Promotes Survival in SERCA2a KO Heart Failure Mice
Mediators Inflamm, 2017, 9450439
DOI 10.1155/2017/9450439, PubMed 28490840
Interleukin 27 is increased in carotid atherosclerosis and promotes NLRP3 inflammasome activation
PLoS One, 12 (11), e0188387
DOI 10.1371/journal.pone.0188387, PubMed 29176764
Publications 2016
Low Circulating Levels of Mitochondrial and High Levels of Nuclear DNA Predict Mortality in Chronic Heart Failure
J Card Fail, 22 (10), 823-8
DOI 10.1016/j.cardfail.2016.06.013, PubMed 27349571
Palmitate promotes inflammatory responses and cellular senescence in cardiac fibroblasts
Biochim Biophys Acta Mol Cell Biol Lipids, 1862 (2), 234-245
DOI 10.1016/j.bbalip.2016.11.003, PubMed 27845246
Response to letter from Toldo et al. on "NLRP3 inflammasome activation during myocardial ischemia reperfusion is cardioprotective"
Biochem Biophys Res Commun, 474 (2), 328-329
DOI 10.1016/j.bbrc.2016.04.096, PubMed 27109473
Publications 2015
Sustained Toll-Like Receptor 9 Activation Promotes Systemic and Cardiac Inflammation, and Aggravates Diastolic Heart Failure in SERCA2a KO Mice
PLoS One, 10 (10), e0139715
DOI 10.1371/journal.pone.0139715, PubMed 26461521
NLRP3 inflammasome activation during myocardial ischemia reperfusion is cardioprotective
Biochem Biophys Res Commun, 469 (4), 1012-20
DOI 10.1016/j.bbrc.2015.12.051, PubMed 26706279
Publications 2014
Double blockade of CD14 and complement C5 abolishes the cytokine storm and improves morbidity and survival in polymicrobial sepsis in mice
J Immunol, 192 (11), 5324-31
DOI 10.4049/jimmunol.1400341, PubMed 24790148
Toll-like receptor 9 mediated responses in cardiac fibroblasts
PLoS One, 9 (8), e104398
DOI 10.1371/journal.pone.0104398, PubMed 25126740
Publications 2013
The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury
Cardiovasc Res, 99 (1), 164-74
DOI 10.1093/cvr/cvt091, PubMed 23580606
A role for NLRP3 inflammasome in acute myocardial ischaemia-reperfusion injury? Reply
Cardiovasc Res, 99 (1), 226-7
DOI 10.1093/cvr/cvt130, PubMed 23708737
Publications 2012
The homeostatic chemokine CCL21 predicts mortality and may play a pathogenic role in heart failure
PLoS One, 7 (3), e33038
DOI 10.1371/journal.pone.0033038, PubMed 22427939
Increased interleukin-1β levels are associated with left ventricular hypertrophy and remodelling following acute ST segment elevation myocardial infarction treated by primary percutaneous coronary intervention
J Intern Med, 272 (3), 267-76
DOI 10.1111/j.1365-2796.2012.02517.x, PubMed 22243053
Publications 2011
Cellular sources and inducers of cytokines present in acute wound fluid
Wound Repair Regen, 19 (3), 337-47
DOI 10.1111/j.1524-475X.2011.00668.x, PubMed 21371163
Publications 2009
IL-10 enhances MD-2 and CD14 expression in monocytes and the proteins are increased and correlated in HIV-infected patients
J Immunol, 182 (1), 588-95
DOI 10.4049/jimmunol.182.1.588, PubMed 19109192
Publications 2006
Endocytic pathways regulate Toll-like receptor 4 signaling and link innate and adaptive immunity
EMBO J, 25 (4), 683-92
DOI 10.1038/sj.emboj.7600991, PubMed 16467847